Saturn V Capital Management LP: AMYLYX PHARMACEUTICALS INC (AMLX): Quarterly 13F Position History
As of Q2 2026, Saturn V Capital Management LP reported 4,624,101 shares of AMYLYX PHARMACEUTICALS INC (AMLX), worth $83.0M and representing 11.9% of its 13F equity book. Quarter-over-quarter share count change: + 274,216 (+6.3%) . The position first appeared in Q3 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 4,624,101Shares Held (Latest Filing)
- $83.0MReported Market Value (Latest Filing)
- 11.9%Portfolio Weight (% of 13F Equity Book)
- +274,216Quarter-over-Quarter Share Change
- +$22.6MQuarter-over-Quarter Value Change
- 4,624,101Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,624,101 | +274,216 | +6.3% | $83.0M | 11.9% | $18.0 |
| Q1 2026 | 4,349,885 | 146,602 | -3.3% | $60.5M | 10.9% | $13.9 |
| Q4 2025 | 4,496,487 | 108,391 | -2.4% | $54.3M | 10.0% | $12.1 |
| Q3 2025 | 4,604,878 | +1,344,308 | +41.2% | $62.6M | 13.7% | $13.6 |
| Q2 2025 | 3,260,570 | +834,134 | +34.4% | $20.9M | 8.5% | $6.4 |
| Q1 2025 | 2,426,436 | +1,537,363 | +172.9% | $8.6M | 4.3% | $3.5 |
| Q4 2024 | 889,073 | +889,073 | – | $3.4M | 1.3% | $3.8 |
| Q3 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2024 | 0 | 1,099,268 | -100.0% | $0 | 0.0% | – |
| Q4 2023 | 1,099,268 | +213,125 | +24.1% | $16.2M | 6.2% | $14.7 |
| Q3 2023 | 886,143 | – | – | $16.2M | 6.8% | $18.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Saturn V Capital Management LP first disclose a AMLX position in 13F-HR filings?
Saturn V Capital Management LP first reported AMYLYX PHARMACEUTICALS INC (AMLX) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Saturn V Capital Management LP's most recent quarter-over-quarter share-count change in AMLX?
Between Q1 2026 and Q2 2026, Saturn V Capital Management LP added 274,216 shares of AMLX (+6.3%), bringing the total reported position to 4,624,101 shares at a market value of $83.0M.
Does the implied price-per-share represent Saturn V Capital Management LP's cost basis in AMLX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.